Results 171 to 180 of about 212,526 (280)

Inhibition of Bruton’s Tyrosine Kinase Activity Attenuates Hemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats

, 2021
Nikita M. Patel, Filipe R. M. B. Oliveira, Hanna Pillmann Ramos, Eleonora Aimaretti, Gustavo Ferreira Alves, Sina M. Coldewey, Massimo Collino, Regina Sordi, Christoph Thiemermann   +8 more
openalex   +1 more source

Phosphatidylinositol 3-kinase-γ activates Bruton’s tyrosine kinase in concert with Src family kinases

, 1997
Zuomei Li, Matthew I. Wahl, A. Eguinoa, Leonard R. Stephens, Phillip T. Hawkins, Owen N. Witte   +5 more
openalex   +1 more source

Role of Bruton’s tyrosine kinase inhibitors in HIV-1-infected cells

, 2015
Irene Guendel, Sergey Iordanskiy, Gavin C. Sampey, Rachel Van Duyne, Valerie Calvert, Emanuel Petricoin, Mohammed Saifuddin, Kylene Kehn‐Hall, Fatah Kashanchi   +8 more
openalex   +2 more sources

Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis [PDF]

, 2023
Je-Young Shin, Suk‐Won Ahn
openalex   +1 more source

Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase [PDF]

, 2018
Christopher M. Harris, Sage E. Foley, Eric R. Goedken, Mark Michalak, Sara Murdock, Noel S. Wilson   +5 more
openalex   +1 more source

Novel Bruton’s Tyrosine Kinase (BTK) Substrates for Time-Resolved Luminescence Assays [PDF]

, 2022
Naomi E. Widstrom, Minervo Perez, Erica D. Pratt, Jason L. Heier, John F. Blankenhorn, Lindsay Breidenbach, Hannah Peterson, Laurie L. Parker   +7 more
openalex   +1 more source

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

, 2022
Weam Othman Elbezanti, Omar S. Al‐Odat, Robert Chitren, J Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda, Tülin Budak-Alpdoǧan, Manoj K. Pandey   +11 more
openalex   +1 more source

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia

Journal of Blood Medicine, 2019
Aristea-Maria Papanota,* Ioannis Ntanasis-Stathopoulos,* Efstathios Kastritis, Meletios A Dimopoulos, Maria GavriatopoulouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital,
Papanota AM, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA, Gavriatopoulou M   +4 more
doaj  

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies [PDF]

, 2018
Robert L. Campbell, Geoffrey Chong, Eliza A. Hawkes   +2 more
openalex   +1 more source

Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability

, 2015
Wendy B. Young, J A Barbosa, Peter Blomgren, Meire Bremer, James J. Crawford, Donna M. Dambach, Charles Eigenbrot, Steve Gallion, Adam R. Johnson, Jeffrey E. Kropf, Seung Hwan Lee, Lichuan Liu, Joseph W. Lubach, Jen Macaluso, Pat Maciejewski, Scott A. Mitchell, Daniel F. Ortwine, Julie Di Paolo, Karin Reif, Heleen Scheerens, Aaron C. Schmitt, Xiaojing Wang, Harvey Wong, Jin-Ming Xiong, Jianjun Xu, Christine Yu, Zhongdong Zhao, Kevin Currie   +27 more
openalex   +2 more sources